Skip to main content

Zealand Pharma to attend Jefferies and Goldman Sachs Virtual Healthcare Conferences

Written by Customer Service on . Posted in Public Companies.

Press release – No. 06 / 2020Zealand Pharma to attend Jefferies and Goldman Sachs Virtual Healthcare ConferencesCopenhagen, June 1, 2020 – Zealand Pharma A/S (Nasdaq: ZEAL), a biotechnology company changing lives with innovative peptide-based medicines, will participate in two upcoming investor conferences.On June 4, 2020, Chief Executive Officer Emmanuel Dulac and Chief Financial Officer Matt Dallas will participate in the Jefferies 2020 Virtual Healthcare Conference.  In addition to meeting with individual investors, both executives are scheduled to participate in a “fireside chat” with a research analyst on Thursday, June 4, 2020 from 11:00 to 11:25 AM Eastern. The presentation can be accessed at http://wsw.com/webcast/jeff126/zeal/. A replay of this presentation will be accessible via the same link, and will be available after the conference on the Company’s website http://www.zealandpharma.com.CEO Emmanuel Dulac and CFO Matt Dallas will also participate in the 41st Annual Goldman Sachs Global Healthcare Conference held as a virtual event June 9-11, 2020. A company presentation is planned for June 11, 2020 at 10:30 AM Eastern. For more information, please refer to the event website at http://www.goldmansachs.com/gsevents/hcc2020.# # #About Zealand Pharma A/S
Zealand Pharma A/S (Nasdaq: ZEAL) (“Zealand”) is a biotechnology company focused on the discovery, development, and commercialization of next generation peptide-based medicines that change the lives of people living with metabolic and gastrointestinal diseases. More than 10 drug candidates invented by Zealand have advanced into clinical development, of which two have reached the market. Zealand’s robust pipeline of investigational medicines includes three candidates in late stage development, and one candidate being reviewed for regulatory approval in the United States. Zealand markets V-Go®, an all-in-one basal-bolus insulin delivery option for people with diabetes. License collaborations with Boehringer Ingelheim and Alexion Pharmaceuticals create opportunity for more patients to potentially benefit from Zealand-invented peptide therapeutics.Zealand was founded in 1998 in Copenhagen, Denmark, and has presence throughout the U.S. that includes key locations in New York, Boston, and Marlborough (MA). For more information about Zealand’s business and activities, please visit http://www.zealandpharma.com.For further information, please contact:Zealand Pharma Investor Relations
+45 50 60 38 00
investors@zealandpharma.comLani Pollworth Morvan, Investor Relations and Communication
LMorvan@zealandpharma.comAttachment06-20_0601_Zealand Pharma attends Jefferies and Goldman Sachs

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.